Related Experiment Video
Updated: May 10, 2026

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
Published on: January 7, 2019
Coronary Artery Disease in the Human Immunodeficiency Virus Seropositive Population
Michael G Barakat1, Rohit R Arora
11Chicago Medical School, North Chicago, IL; and 2Department of Medicine, Chicago Medical School, North Chicago, IL.
Insights
Human immunodeficiency virus (HIV) patients face increased coronary artery disease risk due to viral effects, antiretroviral drugs, and metabolic issues. A multifactorial approach is crucial for understanding this link.
Area of Science:
- Cardiology
- Infectious Diseases
- Endocrinology
Background:
- Combined antiretroviral therapies have improved human immunodeficiency virus (HIV) patient lifespan, making it a chronic condition.
- Despite treatment, HIV-infected individuals have a higher risk of coronary artery disease (CAD) compared to the general population.
- Coronary atherosclerosis is a prevalent condition in HIV patients, exacerbated by viral agents and antiretroviral drugs, particularly protease inhibitors.
Purpose of the Study:
- To explore the multifactorial relationship between HIV infection and coronary artery disease.
- To identify key contributing factors to increased CAD risk in HIV patients.
Main Methods:
- Review of existing literature on HIV, antiretroviral therapy, and cardiovascular disease.
- Analysis of factors contributing to metabolic dysfunction and premature aging in HIV patients.
- Consideration of opportunistic infections and vitamin D status in the context of HIV and CAD.
Main Results:
- HIV infection directly contributes to generalized metabolic dysfunctions and premature senescence.
- Antiretroviral drugs, especially protease inhibitors, can accentuate coronary atherosclerosis.
- Co-occurring opportunistic infections and vitamin D deficiency are significant factors in the HIV-CAD correlation.
Conclusions:
- The correlation between HIV and coronary artery disease is multifactorial.
- Addressing metabolic dysfunctions, drug effects, opportunistic infections, and vitamin D levels is essential for managing CAD risk in HIV patients.
Abstract:
The development of efficient combined antiretroviral therapies has lengthened the mean life span of the population affected with human immunodeficiency virus (HIV) transforming this terminal infection to a chronic yet manageable disease. Nonetheless, patients with HIV--treatment naive or not--exhibit larger risks for coronary artery disease than the noninfected population. Moreover, coronary atherosclerosis/arteriosclerosis may be the most prevalent condition in the HIV-infected population that is being accentuated by the effects of viral agents and the antiretroviral drugs, especially protease inhibitors. Nonetheless, generalized metabolic dysfunctions and premature senescence are often attributed to the viremia caused by the HIV infection directly and primarily. Therefore, a multifactorial approach is to be considered when attempting to explain the strong correlation between HIV and coronary artery disease, including co-opportunistic viremias and vitamin D insufficiency/deficiency.
Related Concept Videos
Coronary Artery Disease III: Clinical Manifestations
Coronary Artery Disease I: Introduction
Coronary Artery Disease II: Pathophysiology
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Coronary Artery Disease IV: Preventive Measures
Sexually Transmitted Infections
